Immatics NV (IMTX)

[crudeoil24]

Immatics Sees Positive Data for Cancer Treatment Trials
7:29 am ET March 17, 2021 (Dow Jones) Print

By Chris Wack


Immatics NV said it saw positive clinical data from the dose escalation cohorts of its ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach.

The biopharmaceutical company said the treatment of patients with ACTengine product candidates IMA201, IMA202 and IMA203 at initial dose levels below one billion transduced cells intended to establish safety and first biological activity, showed first anti-tumor activity with 9 out of 10 evaluable patients showing disease control as well as tumor shrinkage observed in 8 out of 10 patients including one partial response.

Immatics said clinical observations were consistent with observed robust engraftment, persistence and tumor infiltration of infused ACTengine T cells. Overall, all product candidates demonstrated a manageable safety and tolerability profile.

The primary objectives of the Phase 1 studies are to study the safety profile of the ACTengine product candidates in patients with target-positive solid cancers and to determine the recommended Phase 2 dose. Secondary objectives include the assessment of T cell engraftment, persistence and infiltration into the tumor, and the assessment of objective tumor responses.

ACTengine product candidates were well tolerated. All adverse events were transient and manageable. No dose-limiting toxicities were observed in patients treated with IMA201 and IMA202. One patient receiving IMA203 at dose level 2 experienced a dose limiting toxicity as defined in the trial protocol. The reaction was transient and fully resolved within 48 hours after onset.

Immatics shares were up 12%, to $13, in premarket trading.